Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas

Clinical Feasibility and Potential Clinical Benefit of 68Ga-DOTATATE PET/CT Assessment of Soft Tissue Sarcomas for Potential Peptide Receptor Radionuclide Therapy

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This trial studies how well 68Ga-DOTATATE digital PET/CT work in diagnosing soft tissue sarcoma. 68Ga-DOTATATE is a radiotracer that may improve image quality of PET imaging. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-DOTATATE. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. 68Ga-DOTATATE digital PET/CT may work better in imaging patients with soft tissue sarcomas.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients \>= 18 years of age - Patients diagnosed with any stage of soft tissue sarcomas candidates for systemic therapies - Patients with one standard of care PET/CT scan up to 30 days before enrollment at the Ohio State University facilities. Who Should NOT Join This Trial: - Hypersensitivity to somatostatin or similar peptides - Somatostatin long-acting analog in the past 6 months - Patients who are pregnant or lactating - Patients who are currently incarcerated - Patients with acute infections - Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) - Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the dPET/CT scanner due to body mass index (BMI) Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients \>= 18 years of age * Patients diagnosed with any stage of soft tissue sarcomas candidates for systemic therapies * Patients with one standard of care PET/CT scan up to 30 days before enrollment at the Ohio State University facilities. Exclusion Criteria: * Hypersensitivity to somatostatin or similar peptides * Somatostatin long-acting analog in the past 6 months * Patients who are pregnant or lactating * Patients who are currently incarcerated * Patients with acute infections * Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) * Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the dPET/CT scanner due to body mass index (BMI)

Treatments Being Tested

PROCEDURE

Computed Tomography

Undergo dPET/CT

RADIATION

Gallium Ga 68-HA-DOTA-TATE

Given IV

PROCEDURE

Positron Emission Tomography

Undergo dPET/CT

Locations (1)

Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States